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Background: NanoString’s Prosigna™ Breast Cancer Prognostic Gene Signature Assay is based on the PAM50 gene
expression signature. The test outputs a risk of recurrence (ROR) score, risk category, and intrinsic subtype (Luminal
A/B, HER2-enriched, Basal-like). The studies described here were designed to validate the analytical performance of
the test on the nCounter Analysis System across multiple laboratories.
Methods: Analytical precision was measured by testing five breast tumor RNA samples across 3 sites. Reproducibility
was measured by testing replicate tissue sections from 43 FFPE breast tumor blocks across 3 sites following independent
pathology review at each site. The RNA input range was validated by comparing assay results at the extremes of the
specified range to the nominal RNA input level. Interference was evaluated by including non-tumor tissue into the test.
Results: The measured standard deviation (SD) was less than 1 ROR unit within the analytical precision study and the
measured total SD was 2.9 ROR units within the reproducibility study. The ROR scores for RNA inputs at the extremes
of the range were the same as those at the nominal input level. Assay results were stable in the presence of moderate
amounts of surrounding non-tumor tissue (<70% by area).
Conclusions: The analytical performance of NanoString’s Prosigna assay has been validated using FFPE breast tumor
specimens across multiple clinical testing laboratories.
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Molecular biomarkers have played an increasingly im-
portant role in identifying cancer patients with different
prognostic outcomes and in predicting response to
chemotherapy [1-3]. Molecular assays targeting these
biomarkers are now routinely performed in local path-
ology labs to help guide treatment decisions in breast
cancer [4,5], lung cancer [6], and colorectal cancer [7].
Gene expression analysis has helped identify distinct* Correspondence: torsten@mail.ubc.ca
1British Columbia Cancer Agency, 3427 - 600 W 10TH Avenue, V5Z 4E6
Vancouver, BC, Canada
4Anatomical Pathology JPN 1401, Vancouver Hospital, 855 W. 12th Ave, V5Z
1 M9 Vancouver, BC, Canada
Full list of author information is available at the end of the article
© 2014 Nielsen et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.molecular signatures in breast cancer that have different
prognostic outcomes [8-10]. Multigene assays targeting
21 – 70 genes are now routinely used in clinical practice
to assess risk of recurrence in early stage breast cancer
[11,12], and prospective clinical trials are also underway
to provide further supporting evidence for the clinical
utility of these assays [13,14]. To date, breast cancer
multigene clinical assays have been largely limited to
central reference laboratories due to the complexity of
performing the test. Ultimately, development of assays
with a simplified workflow is required to move these
multigene expression tests into the local pathology lab
setting, where efficiencies such as shorter turnaroundLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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cians and the clinicians will benefit active patient care.
The PAM50 gene signature measures the expression
levels of 50 genes in a surgically resected breast cancer
sample to classify a tumor as one of four intrinsic subtypes
(Luminal A, Luminal B, HER2-enriched, and Basal-like)
[15], which have been shown to be prognostic in both un-
treated (i.e. no adjuvant systemic therapy) and tamoxifen
treated patient populations [15,16]. In addition to identify-
ing a tumor’s intrinsic subtype, the PAM50 signature gen-
erates an individualized score estimating a patient’s
probability of disease recurrence by weighting the molecu-
lar subtype correlations, a subset of proliferation genes,
and pathologic tumor size [15,16]. The PAM50 test was
adapted to be performed using the nCounter Analysis Sys-
tem in order to develop a simplified workflow that could
be performed in a local pathology lab (Prosigna™ Breast
Cancer Gene Signature Assay, NanoString Technologies,
Seattle). This technology uses multiplexed gene-specific
fluorescently-labeled probe pairs [17] to measure gene ex-
pression in frozen or formalin-fixed paraffin-embedded
(FFPE) tissues with equivalent ease and efficiency [18]. A
recent clinical validation performed on RNA extracted
from over 1000 FFPE tumor specimens from the ATAC
clinical trial demonstrated that the Prosigna risk of recur-
rence (ROR) score, based on the PAM50 gene expression
signature, added significant prognostic information be-
yond the Oncotype DX® Recurrence Score® in estimating
the likelihood of distant recurrence in hormone receptor
positive, post-menopausal breast cancer patients [19]
treated with endocrine therapy alone. A second clinical
validation study performed on over 1400 FFPE patient
samples from the ABCSG-8 trial has independently
confirmed the clinical validity and demonstrated add-
itional prognostic value in node-positive patients and
for the risk of late recurrence [20,21]. Based in part
on the results from these clinical studies and the ana-
lytical studies described herein, NanoString obtained a
CE Mark for its Prosigna assay in 2012, followed by
US Food and Drug Administration (FDA) clearance in
September of 2013.
Recently, requirements for demonstrating utility of a
tumor biomarker were established that include not only
clinical validity, but also analytical reproducibility and
robustness [22,23]. The results of ATAC and ABCSG-8,
including a follow up combined analysis of the two stud-
ies [24] meet this high level of evidence (Level I) for
clinical validity using archived specimens [22]. The stud-
ies described herein were designed to test the analytical
validity of decentralized use of the Prosigna assay across
multiple clinical testing sites, following established
guidelines [25]. These studies were also designed to val-
idate procedures for training laboratory personnel to
perform the Prosigna assay on the nCounter system.Methods
NanoString Prosigna assay
The tissue input for the Prosigna assay was FFPE tissue
that had been previously diagnosed to contain viable in-
vasive breast carcinoma. The breast tumor tissue must
be classified by a pathologist as invasive carcinoma
(ductal, lobular, mixed, or no special type). A pathologist
reviews an H&E stain of a slide mounted tumor section
to identify and circle the region of viable invasive breast
carcinoma. The tumor surface area on the H&E stained
section must be ≥ 4 mm2 per slide, with tumor cellular-
ity ≥ 10%. Non-tumor tissue from outside the circled
area is removed by macrodissection of the correspond-
ing unstained slides. RNA was extracted from slide
mounted breast tissue sections using a RNA extraction
kit manufactured by Roche to NanoString’s specifica-
tions [26]. For RNA isolation, a single 10-micron slide
mounted tissue section was input for RNA extraction
when the tumor surface area measured ≥ 100 mm2,
whereas 3 slides were input when the tumor surface
measured 4-99 mm2. Following extraction of total RNA
and removal of genomic DNA, RNA was eluted (30 μL
volume) and tested to ensure it met the specifications
for concentration (≥ 12.5 ng/ μL) and purity (OD 260/
280 nm 1.7-2.5).
The NanoString Prosigna assay [26] measures the ex-
pression levels of 50 target genes plus eight constitu-
tively expressed normalization genes [15,27,28]. Assay
controls are included to ensure that test samples and the
test process meet pre-defined quality thresholds. Ex-
ogenous probes with no sequence homology to human
RNA sequences are included as positive and negative
assay controls. Positive controls are comprised of a six
point linear titration of in vitro transcribed RNA cover-
ing an approximately 1000 fold RNA concentration
range (0.125 – 128 fM) and corresponding probes
[29,30]. Negative controls consist of a set of probes with-
out the corresponding targets. Each assay run includes
two reference control samples comprising in vitro tran-
scribed RNA of the 58 targets for qualification and
normalization purposes.
Extracted RNA samples meeting quality and concen-
tration specifications were hybridized (without reverse
transcription or amplification) to capture and reporter
probes for the measured genes and assay controls. The
multiplexed hybridizations are carried out in a single-
tube for 15 – 21 hrs at 65°C using 125 – 500 ng RNA
(nominal input of 250 ng). After hybridization, the
target-probe complexes were processed on the nCounter
Analysis System. Test sample data must meet a mini-
mum threshold for expression of normalizing genes to
ensure that the assay signal is high enough for the algo-
rithm to produce precise results. The linearity of the
positive control target titration and the non-specific







Luminal A 30 Low
Luminal B #1 54 Intermediate
Luminal B #2 64 High
Basal-like 55 Intermediate
HER2-enriched 76 High
Molecular characteristics of the five pooled breast tumor RNA samples used in
the RNA precision study.
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each assay is used to determine whether each assay per-
formed within specification. Since the test is designed to
be run in local molecular pathology labs, all quality
thresholds are applied automatically to the data by em-
bedded software; any failing metric causes an assay fail-
ure notice which prevents output of a Prosigna assay
result. For samples meeting all quality thresholds, a clin-
ically validated algorithm is used to determine the intrin-
sic subtype and ROR score, which are prognostic
indicators of risk of distant recurrence of breast cancer
[19,21]. The normalized gene expression profile of each
breast tumor sample is correlated to prototypical gene
expression profiles of the four breast cancer intrinsic
subtypes (Luminal A, Luminal B, HER2-enriched, and
Basal-like). The primary tumor size (categorical input
of ≤ 2 cm or > 2 cm) and normalized gene expression
profile of each breast tumor sample is used to calculate
the numerical ROR score. Risk categories are assigned to
allow interpretation of the ROR score by using pre-
specified cutoffs (defined in a clinical validation study)
related to risk of distant recurrence after 10 years [19].
Operators for these studies were required to undergo
training procedures to demonstrate proficiency, equiva-
lent to what will be used to train users in molecular
pathology laboratories for the decentralized test. Each
site was given an overview of the NanoString technology
and Prosigna assay procedures followed by an in-lab ex-
ercise where users were trained and qualified on tissue
processing and assay procedures (requiring 10-12 hours
of total hands-on time). Briefly, each user extracted RNA
from three FFPE breast tumor tissue samples to demon-
strate proficiency in tissue processing, and each user proc-
essed four prototypical breast tumor RNA samples (one of
each intrinsic subtype with known expected ROR score
values) along with a negative control sample to demon-
strate proficiency on the nCounter Analysis System.
The analytical studies described herein were performed
using pre-specified SOPs, statistical analysis plans and ac-
ceptance criteria using clinical-grade reagents, instrumen-
tation, and software formatted such that no comparison of
results between test centers could even be possible until
the study was completed.
RNA precision: study design
The RNA Precision study assessed the reproducibility of
the Prosigna assay using a common template of purified
RNA, thereby isolating the device-specific components
of analytical validity from variables associated with tissue
processing. The experimental design for analytically val-
idating the precision of the assay from RNA was based
on Clinical Laboratory and Standards Institute (CLSI)
guidelines for the evaluation of precision of in vitro diag-
nostic devices outlined in EP05-A2 [25]. This designmeasured the variability between and within a number
of assay variables including testing site (n = 3), operator
(n = 6), reagent lot (n = 3) and assay run (n = 18/site). Two
of the three sites used were CLIA-certified, CAP-accredited
laboratories at the British Columbia Cancer Agency
(Vancouver), and Washington University (St. Louis); the
third site was NanoString Technologies (Seattle).
Five pooled breast tumor RNA samples were gener-
ated from archived FFPE breast tumor tissue samples
containing viable invasive breast carcinoma, to comprise
a sample set representing each intrinsic breast cancer
subtype and risk classification group (Table 1). Since the
samples were pooled breast tumor RNA, a default tumor
size category of ≤ 2 cm was used to determine the esti-
mated ROR score, and a default nodal status of node-
negative was used to determine risk category. This design
ensured that the prototypical gene expression profiles en-
countered during routine testing were represented within
this analytical validation study. Since Luminal subtypes
make up the vast majority of the intended use population
(hormone receptor positive patients), the study design
included three Luminal samples to span the risk classifica-
tion groups. The identity of each sample aliquot was de-
identified using labeled sample tubes with unique,
randomly assigned, barcoded IDs to ensure that the opera-
tors were blinded to any possible expected results of each
test sample.
Single use aliquots of each pooled breast tumor RNA
sample and three reagent lots were distributed to each
of the three testing sites to complete the following test-
ing scheme (Figure 1). Each of the five RNA pooled sam-
ples was tested in duplicate during each run at the
nominal RNA input level for the assay of 250 ng. The
positions of the tumor RNA samples within the system
(cartridge and strip tube position) were pre-assigned in a
randomized and balanced manner for each run. Each
operator completed one run on a given day since the
assay includes an overnight hybridization step qualifying
it as a “long run method” per CLSI EP05-A2. Following
a device and study protocol familiarization run, each site
completed 18 valid runs (9 by each operator) (Figure 1).
Figure 1 Overview of the design for the RNA precision validation study. Five pooled breast tumor RNA samples were tested across several
sites, operators, reagent lots, and runs.
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collected from each site and merged with the expected
test result and study variables (site, operator, reagent lot,
etc.) associated with each unique sample ID. The pro-
spectively defined analysis plan was then executed on
the merged analysis dataset.RNA precision: statistical analysis
The pre-specified primary aim of the RNA precision val-
idation was to demonstrate that there was no significant
differences for the continuous ROR score assay output
across the three testing sites.
The following variance components model was used
to characterize the sources of variability:
ROR Score = site + operator + lot + run + within-run
where all components were treated as random compo-
nents, and the RNA assay component of variation was
defined as the sum of all these components. Variance
components were estimated using the R procedure
“lmer”. To test whether sites were significantly different,
the following versions of the above model were fitted:
ROR Score = site + operator + lot + run + within-run
& ROR Score = operator + lot + run + within-run
where site was now treated as fixed and all other com-
ponents were treated as random. A likelihood ratio testwith 2-degrees of freedom was performed using the fit-
ted models to determine whether the effect of site was
significant (α = 0.05). A similar analysis was performed
for the assay reagent lots.
For each of the 5 pooled samples, the classifications
into the 4 intrinsic subtype categories (Luminal A, Lu-
minal B, Basal-Like, HER2-enriched) were summarized
using frequency tables.
Reproducibility: study design
The reproducibility study assessed the analytical valid-
ity of the Prosigna assay, including all steps involving
in clinical lab implementation (i.e. tissue handling and
RNA isolation SOPs as well as the device-specific
assay steps), using a common set of breast cancer tis-
sue samples.
The experimental design for analytically validating the
reproducibility from tissue was based on CLSI guidelines
for the evaluation of precision of in vitro diagnostic de-
vices outlined in CLSI EP05-A2. This design allows for
the measurement of variability between and within a
number of assay variables including testing site, FFPE
sample block, operator, reagent lot, and assay run.
A set of 43 banked FFPE breast tumor blocks from
hormone receptor positive breast cancer patients with
confirmed invasive breast carcinoma was selected from
the biobank at Washington University at St. Louis for
this reproducibility validation study. The sample collection
and conduct of this study were conducted in compliance
with the study protocols and local IRB procedures. One
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criteria:
1. Every case should represent a unique breast cancer
patient
2. All must be primary breast cancers
3. All are pathology confirmed invasive ductal or
lobular carcinoma, a mixtures of these types, or
classified as no special type
4. All are hormone receptor positive (ER + or PgR+)
breast cancer
5. All must have a recorded tumor size
6. FFPE blocks should be < 10 years old
7. A minimum of 10 cases each of ≥ 100 mm2 tumor
area (1 slide/test) and 4 - 100 mm2 tumor area
(3 slides/test)
The criterion that at least 10 cases contain ≥ 100 mm2
and at least 10 cases contain 4 - 99 mm2 tumor area
was implemented to validate the number of slides re-
quired for the assay. The blocks were not prescreened
with the assay prior to inclusion, but it was anticipated
that the 43 samples would cover a broad range of ROR
scores representative of the intended use population,
including both node-negative and node-positive pa-
tients, and each risk classification group. Seventeen tis-
sue samples were from node-negative patients, 6 from
node-positive patients and 20 were from patients whose
regional lymph node status was provided by the bio-
bank as NX.Figure 2 Overview of the design for the tissue reproducibility validat
different sites, pathologists, operators, and RNA isolation kits.For reproducibility testing (Figure 2), three sets of seri-
ally cut sections, each comprised of one H&E 4-micron
stained slide and three 10-micron thick unstained slides,
were prepared from each FFPE block. All cut and slide
mounted sections were shipped to NanoString and then
one set from each of the 43 blocks was distributed to the
appropriate testing site for processing. All 43 specimens
were reviewed independently by a separate pathologist for
each of the three sites.
For each tissue sample, a test run consisting of macro-
dissection, RNA extraction, and testing with the Pro-
signa assay was performed by a single operator at each
site following the provided standard operating proce-
dures. Each operator performed a minimum of four test
runs consisting of up to 10 tissue samples per run. Each
batch of tissue samples required a minimum run time of
3 days from tissue processing to result. Isolated RNA
that met the quantity and quality specifications from
each of the slide mounted sections was tested twice in
separate assay runs. Different lots of RNA isolation kit
reagents were used at each site, and a single lot of the
Prosigna assay kit was used at all three sites.
The test results for all samples remained blinded to all
personnel at all sites until the study was complete. Upon
completion of the study the blinded Prosigna assay data
were collected from each site and merged with the ex-
pected test result and study variables (site, operator, re-
agent lot, etc.) associated with each unique sample ID.
The prospectively defined analysis plan was then exe-
cuted on the merged analysis dataset.ion study. Tissue samples (1-43) were processed in parallel across
Figure 3 Overview of the design for the RNA input study. RNA
from 13 tissue samples was tested across and beyond the RNA input
range specified for the assay.
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The pre-specified primary aim of the tissue reproducibil-
ity validation was to demonstrate the Prosigna assay is
highly reproducible, when combining all sources of vari-
ation. For this study, “highly reproducible” was defined
as a total standard deviation (SD) of less than 4.3 ROR
units. The value of <4.3 was chosen because if two sam-
ples have true ROR scores that differ by 10 units, a total
SD of 4.3 means that 95% of the time the higher of the
two will still have a higher individual observed ROR
score. A change of 10 ROR units corresponds to an aver-
age change in 10-year distant recurrence free survival of
7% and 6% for node negative and node positive patients
respectively [19].
The following variance components model was used
to characterize the sources of variability:
Measurement = FFPE Block + site + tissue section
+ error
where FFPE Block was treated as a fixed component,
and site and section were treated as random compo-
nents. The “site” term measured the systematic site-
specific variation that was constant across all tissue
samples (pathologist, technician, extraction kit). The tis-
sue section component measures random variation that
differed as a function of review/processing or within
FFPE block variation. The error term was derived from
the duplicate RNA samples and estimated the combin-
ation of run-to-run and within-run variance. Variance
components were estimated using the R procedure
“lmer”. In the above model, the variance components
were estimated from a combined analysis of all FFPE
blocks after verifying that were no systematic changes in
tissue-specific variation as a function of ROR score.
The tissue and RNA isolation components were esti-
mated using the reproducibility validation and the assay
components were estimated using the RNA precision
validation. The total variability, σ2total , was calculated as:
σ2total ¼ σ2tissue þ σ2RNAassay
where σ2tissue was estimated as the sum of the site-to-site
and section component estimated in the tissue reprodu-
cibility study, and σ2RNAassay was estimated as the total
variation from the RNA precision study.
Additional categorical analyses were performed using
two classifications:
 3 risk-categories (low, intermediate, and high) using
both the node-negative and node-positive cutoffs,
 4 intrinsic subtype categories (Luminal A, Luminal
B, Basal-Like, HER2-enriched)RNA from each tissue sample was tested twice at each
site so there are 4 possible comparisons between sites
for each tissue sample leading to a total number of pos-
sible comparisons of 4*number of tissue samples. For
each of the two classification schemes (risk category or
subtype), the pair-wise concordance between sites was
estimated as the fraction of all possible comparisons that
were concordant and an exact-type 95% confidence
interval was calculated.
In addition, a post hoc analysis compared the normal-
ized gene expression from the 50 classifier genes be-
tween the tissue replicates from all valid specimens
tested at each site using a linear regression and correl-
ation analysis
RNA input: study design
Thirteen FFPE breast tumor blocks containing pathologically-
confirmed infiltrating ductal carcinoma were obtained and
RNA was extracted from multiple slide mounted tissue
sections from each block using the defined procedure
(Figure 3). The individual RNA isolates from each FFPE
block were pooled. Each pooled tumor RNA sample was
tested in duplicate across three RNA input levels within
the assay specification range (500, 250, and 125 ng) and in
singlet at two additional RNA input levels outside of the
specification range (625, 62.5 ng). Two no-target (water)
measurements were also tested in duplicate on every run.
All tumor RNA samples were assumed to be node-
negative with a tumor size of ≤ 2 cm for this analytical
study since these clinical covariates have no impact on the
measured variation in the ROR score. All samples were
tested using two different Prosigna assay reagent lots.
RNA input: statistical analysis
The pre-specified primary aim of the RNA input study
was to demonstrate the Prosigna assay results were
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range (125 and 500 ng RNA) regardless of the assay re-
agent kit lot used. For each kit lot, the test statistic was
the average difference between the mean ROR score at a
given input level RORLj
 
and the mean ROR score at
the nominal level RORNj
 
:






where the average is across the n different samples. In
this equation, RORNj is the average of two replicates at
the nominal level and RORLj s the average of two repli-
cates for input levels within specification, or is the single
result for input levels outside of specification. Equiva-
lence was pre-defined as an observed absolute average
ROR difference significantly less than 3. To test the non-
equivalence hypothesis that the true absolute mean dif-
ference is greater than 3, a 90% confidence interval for
the difference was calculated. This 90% confidence inter-
val corresponds to the two one-sided test approach for
bioequivalence [31]. The input level was determined to
be equivalent to the nominal level if the 90% confidence
interval is completely contained within -3 and 3.
For each pooled sample a linear regression and correl-
ation analysis was also performed between each replicate
at each RNA input level and one of the two replicates
run at 250 ng of RNA. The difference in the ROR score
(ΔROR) from the nominal RNA input level (250 ng) for
each replicate at each RNA input level was calculated by
subtracting the ROR score calculated from one of the
two replicates run at 250 ng from ROR scores calculated
at the other input levels. Additionally, the ΔROR was
calculated and linear regression and correlation analyses
were also performed between the two replicates at
250 ng. The mean ΔROR, slope, intercept, and correl-
ation values (with 95% confidence intervals) were calcu-
lated using the pairwise comparisons for all passing
samples at each input level for both kit lots.
For the no-target (water) samples, the percentage of
samples failing the minimum threshold for expression of
normalizing genes was calculated. All no-target samples
were required to give a failing test result.
Tissue interferents: study design and analysis
Twenty three FFPE breast tumor blocks were obtained
containing pathologically-confirmed infiltrating ductal
carcinoma microscopically-assessed to have 10 – 95% of
the total tissue area containing normal/non-tumor tis-
sue. Pathologists identified additional tumor interferents
(DCIS, necrotic tissue, or blood/hemorrhagic tissue)
within or near the margins of the tumor in ten of the 23
blocks.For each FFPE breast tumor block, H&E stained slides
were prepared and up to nine unstained sections were
cut and mounted on slides. For the inclusion of the
interferent, the sections were processed according to the
assay procedure with the exception that identified nor-
mal/non-tumor tissue or any additional interferents were
included in the isolation (“non-macrodissected slides”).
For the macrodissection where the non-tumor and other
interferents were removed, three or (in the case of small
tumor surface areas) three and six slides were processed
according to the Prosigna assay protocol.
The change in ROR (ΔROR) due to the interferent
was calculated using the ROR score from the non-
macrodissected slides minus the ROR score from the
macrodissected slides (Figure 4). For the tissue blocks
where three and six macrodissected slides were inde-
pendently isolated and both produced a passing assay re-
sult, the average of the two ROR scores were used to
calculate the ΔROR.
Results
RNA precision: variance components analysis
The precision of the Prosigna assay starting from RNA was
assessed with 5 pooled breast tumor RNA samples each
tested 36 times at each of the three sites. There were no in-
dividual test samples that failed the pre-specified data QC
metrics in the software so the analysis includes 540 results
from 54 valid runs. For all five tumor RNA samples, the
total SD was less than 1 ROR unit on a 0 - 100 scale
(Table 2), and there was 100% concordance between mea-
sured subtype result and expected subtype result as well as
measured and expected risk group. More than 60% of
the measured variability came from within-run variance
(repeatability) while less than 2% of the variance was
attributable to site-to-site variance or operator-to-operator
variance. The differences in mean ROR scores between sites
were less than 0.5 ROR units on a 0-100 scale and were
insignificant for all tested samples (Additional file 1:
Table S1). The contribution to overall variance by the three
reagent lots was approximately 20% of the total variance on
average, but the differences were all less than 1 ROR unit.
At each site, the normalized gene expression between RNA
replicates was highly correlated with slopes ranging from
0.98 – 1.00, intercepts at 0, and r values of 0.99.
The distribution of measured ROR scores for each of
the five pooled RNA samples was also examined across
the three lots, six users and three test sites. The range of
ROR scores for the 108 independent measurements was
≤4 units for each of the 5 sample pools (Figure 5).
Reproducibility: test sample quality control and
characterization
The call rate for the 43 tissue samples evaluated was
95%, 93%, and 100% for sites 1, 2, and 3 respectively.
Figure 4 Overview of tissue processing for assessing the effect of tissue interferents. Multiple sections from FFPE breast tumor blocks were
mounted onto slides and processed with or without macrodissection. The change in ROR score (ΔROR) is calculated as the ROR score from the
non-macrodissected slides minus the ROR score from the macrodissected slides (or in the illustration ΔROR = 25 – 30 = -5).
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of one sample at one site required repeating). One tissue
sample yielded results at 2 sites, and 2 samples yielded
results at a single site, while the other sites did not ob-
tain sufficient RNA to perform the assay for these sam-
ples. The measured tumor surface area for 4/5 RNA
isolation failures was very small (≤ 15 mm2). One hun-
dred percent (100%) of samples passing tissue review
and RNA isolation specifications yielded passing results
from the Prosigna assay.
The calculated test results from the 43 tissues
across all sites represent a wide range (94 units) of
ROR scores (Figure 6) and all risk categories when
applying the node-negative or node-positive ROR
score cutoffs to all samples. All four intrinsic subtypes
were also represented among the 43 specimens. The
two samples where RNA could only be successfully
isolated at one site were excluded from all subsequent
statistical analysis as there was no available data for






Reagent lot Site Op
Basal-like 55.4 0.059 (20%) 0.000 (0%) 0.00
HER2-enriched 76.2 0.165 (37%) 0.000 (0%) 0.00
Luminal A 31.4 0.010 (2%) 0.000 (0%) 0.00
Luminal B 1 55.0 0.105 (18%) 0.000 (0%) 0.00
Luminal B 2 64.8 0.119 (21%) 0.014 (2%) 0.00
The percent of total variance is listed below the estimated variance.ROR scores of less than 10 and were classified as
Luminal A.
Reproducibility: variance components analysis
(primary objective)
Table 3 shows the results of the variance components ana-
lysis using all 41 tissue specimens where replicate measure-
ments were available. The “tissue section” variation, which
consists of variation contributed by within FFPE block sec-
tions, pathology review, and tissue processing, was the
dominant source of variation (> 90% of total variance).
The differences on average between the sites were negligible
(< 1% of total variance). The combined run-to-run variabil-
ity and within-run variability in the assay (determined from
the duplicate measurements from each RNA isolation from
the reproducibility study) was consistent with the variability
measured in the RNA-precision study (variance of 0.51
compared to 0.47 for the RNA-precision study).
The total SD including all source of variation (tissue





0 (0%) 0.046 (15%) 0.194 (65%) 0.299 (100%) 0.55
0 (0%) 0.000 (0%) 0.277 (63%) 0.442 (100%) 0.66
0 (0%) 0.134 (30%) 0.296 (67%) 0.44 (100%) 0.66
0 (0%) 0.046 (8%) 0.426 (74%) 0.576 (100%) 0.76
0 (0%) 0.064 (11%) 0.380 (66%) 0.576 (100%) 0.76
Figure 5 Distribution of 108 ROR scores measured for each of the 5 Pooled RNA samples. Boxplots show the distribution of ROR scores
relative to the 0-100 range and the histograms show the frequency of the measured ROR scores on a 20-point range. Boxplots and histograms
are colored by the intrinsic subtype result for each sample.
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ROR scores of 6.75 with 95% confidence.
Reproducibility: subtype and risk category classifications
concordance
The site-to-site concordances for the two categorical
classifications are shown in Table 4, in each case withFigure 6 Reproducibility of the ROR score in the tissue
reproducibility study. Average tissue block ROR compared to the
individual ROR score for all samples. Data are colored by the intrinsic
subtype result. The high, intermediate, and low node negative risk
categories are shown to the right of the figure with the risk thresholds
shown as lines in the body of the figure.exact-type 95% confidence intervals. For each compari-
son (subtype and node negative and positive risk cat-
egories), the average concordance between sites was at
least 90%. There were no samples where the risk cat-
egory changed from low risk to high risk (or vice versa)
between or within sites when the samples were assumed
to be from node negative patients. There were only two
intermediate/high risk samples that did not give identical
subtypes across all 6 replicates:
 One sample had duplicate Luminal A results at one
site and duplicate Luminal B results at each of the
other two sites.
 One specimen had duplicate Luminal A results at
one site, duplicate HER2-enriched results at another
site and one each of Luminal A and HER2-enriched
at the third site.
Reproducibility: pairwise correlation coefficients of gene
expression
The average intercept, slope, and Pearson’s correlation
of the pair-wise comparisons between sites are reportedTable 3 Total variability (from tissue and RNA processing)
of the Prosigna assay






0.10 7.72 0.47 8.29 2.9
The total SD of 2.9 is on a 0-100 ROR scale.
Table 4 Concordance of subtype calls and risk categories between the three sites
Comparison
type
Pairwise Concordance [95% CI] Average
concordanceSite 1 vs. Site 2 Site 1 vs. Site 3 Site 2 vs. Site 3
(n = 40) (n = 41) (n = 40)
Subtype 96.3% 98.8% 95% 97%
[86.4%–99.5%] [91.0%–100%] [83.1%–99.3%]
Risk Category 87.5% 92.7% 90% 90%
(Node Negative) [73.2%–95.8%] [80.1%–98.4%] [76.4%–97.2%]
Risk Category 90.0% 95.1% 95.0% 93%
(Node Positive) [76.9%–96.0%] [83.9%–98.7%] [83.5%–98.6%]
The pairwise (site to site) concordance is reported with the 95% confidence interval.
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pression between tissue replicates was highly correlated
between sites with slopes ranging from 0.97 – 1.00, in-
tercepts at 0, and r values of 0.98 or greater. Equivalent
or higher correlation values were observed when a simi-
lar analysis was performed for the RNA replicates tested
at each site (Additional file 2: Table S2). Additionally,
hierarchical clustering analysis demonstrated that tissue
sample and RNA sample replicates were always and only
clustered together across a wide range of expression in
each of the 50 genes across all samples tested (Additional
file 3: Figure S1).
RNA input: test sample quality control
The average ROR score for the tested samples covered a
broad range (20 – 82) and all intrinsic subtypes – in-
cluding 5 Luminal A, 4 Luminal B, 3 HER2-enriched
and 1 Basal-like sample (Additional file 4: FigureS2).
One FFPE block was tested with a single kit lot due to
insufficient RNA mass from the isolation for the second
lot. Two runs (each with different samples) failed to pro-
vide passing results for one of the two lots tested due to
a processing error detected by system controls withTable 5 Site to site gene expression comparisons from
the tissue reproducibility study
Comparison
Pairwise (n) Intercept Slope Pearson
[95% CI] [95% CI] [95% CI]
All Sites 121 0.00 0.98 0.98
[-0.01–0.01] [0.97–0.99] [0.98–0.98]
Site 1 vs. Site 2 40 0.00 0.97 0.98
[-0.01–0.01] [0.95–0.98] [0.97–0.98]
Site 1 vs. Site 3 40 0.01 1.00 0.98
[0–0.02] [0.98–1.01] [0.98–0.99]
Site 2 vs. Site 3 41 -0.01 0.99 0.99
[-0.02–0] [0.97–1] [0.98–0.99]
Pairwise correlations, slopes, and intercepts of normalized 50 genes for tissues
replicates from the tissue reproducibility study. The average intercept, slope,
and Pearson’s correlation of the pair-wise comparisons are reported with their
95% confidence intervals.insufficient RNA to repeat the assay. All measured no-
target samples (n = 46) were well below the threshold for
signal and yielded a failing test result (0% call rate). All
tumor RNA measurements within assay specification (n =
138) yielded a passing test result (100% call rate). One
hundred percent (100%) of specimens with input above
specification (625 ng) yielded a passing test result. Eighty-
three percent (83%) of specimens (10/12) tested at input
below specification (62.5 ng) yielded a test result in lot 1,
as did 100% in lot 2.
RNA input: ROR score difference and pairwise correlation
coefficients of gene expression
For each of the two reagent lots tested, the confidence
interval around the mean ROR score difference between
the nominal input and the RNA input limits (125 and
500 ng) were completely contained within -3 and 3 ROR
units. The ROR scores at 125 and 500 ng RNA were
therefore equivalent to those at the target input concen-
tration of 250 ng for each of the two reagent kit lots tested
meeting the primary objective of the study. Of note, when
characterizing the RNA levels outside of the assay specifi-
cation, the ROR scores at 62.5 ng RNA were not equiva-
lent (with an upper confidence limit at 3.26) to those at
the target input concentration of 250 ng for one of the
two lots tested. This illustrates the importance of perform-
ing the assay according to the defined procedure.
When the lots were combined the normalized gene ex-
pression values and ROR scores were consistent to those
at the target input concentration of 250 ng within and
even outside the RNA input limit specifications (Table 6).
Characterization of intrinsic subtype across the samples
tested shows a 100% concordance in subtype call across
all samples and inputs. Similarly, there is a 100% concord-
ance by risk classification across all samples and inputs.
Tissue interferents: test sample quality control
Out of 23 samples six were Luminal A, seven were Lu-
minal B, two were HER2-enriched, and eight were Basal-
like. The average ROR score for the 23 samples covered a
broad range (10 – 83), (Additional file 5: Figure S3).
Table 6 Comparison of gene expression at different masses from the RNA input study
Mass (ng) Pairwise (n) Pearson Slope Intercept ΔROR
[95% CI] [95% CI] [95% CI] [95% CI]
62.5 21 0.97 [0.93–0.99] 0.96 [0.91–1.00] -0.02 [-0.05–0.01] 0.48 [-1.27–2.22]
125 46 0.99 [0.97–0.99] 0.98 [0.96–1.01] -0.01 [-0.03–0.01] -0.04 [-0.89–0.8]
250 23 0.99 [0.98–1.00] 1.00 [0.99–1.01] 0.00 [-0.01–0.01] -0.39 [-0.96–0.17]
500 46 0.99 [0.99–1.00] 0.97 [0.96–0.99] 0.02 [0.01–0.04] -0.57 [-1.39–0.26]
625 23 0.99 [0.98–1.00] 0.95 [0.92–0.99] 0.03 [0.01–0.06] -0.78 [-2.2–0.63]
Pairwise correlations, slopes, and intercepts of normalized 50 genes and change in ROR score for replicate RNA Hybridizations with different mass inputs. The
average intercept, slope, Pearson’s correlation, and change in ROR for the pair-wise comparisons are reported with their 95% confidence intervals.
Figure 7 Effect of non-tumor tissue on the ROR score. The
impact of including adjacent non-tumor tissue on ROR was assessed
by determining the change in test results from slide mounted
sections with vs. without macrodissection of adjacent non-tumor
tissue. Data colors represent if the interferent was only normal/non-
tumor tissue or if additional non-tumor interferents (DCIS, necrotic
tissue, or blood/hemorrhagic tissue) were identified within or near
the margins of the tumor.
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As the amount of adjacent non-tumor tissue increases
there is an increasing risk that the reported ROR score
will be an underestimate or negatively biased (up to -19
ROR score units for samples containing 95% non-tumor
tissue) estimate of a patient’s risk of recurrence (Figure 7).
Elimination of the macrodissection step required by the
assay also caused a change in subtype determination for
five out of 23 samples. Three Luminal B samples, one
HER2-enriched, and one basal-like sample were classified
as Luminal A due to inclusion of adjacent non-tumor tis-
sue. In contrast, the presence of intratumor hemorrhage,
necrosis or DCIS (not removed by macrodissection) had
little effect on ROR.
Discussion
Breast cancer gene expression testing has been the sub-
ject of many studies demonstrating its capacity to strat-
ify breast cancers by prognostic risk [9,15,16,32,33].
Increasingly, studies are also showing the value of such
signatures to predict response to therapy, for example by
using these tests to evaluate archival specimens from
randomized clinical trials [34-36]. The integration of
molecular genomic testing into cancer care is an active
area of development, with huge genomic datasets be-
coming available. Great improvements in experimental
design and bioinformatic analysis have led to the devel-
opment of robust signatures ripe for translation into
clinical tests. Studies applying these signatures to differ-
ent clinical series with observational, case-control, co-
hort and randomized trial designs have generated
increasingly strong evidence for clinical validity, particu-
larly in breast cancer [19,34,35,37]. It is in this backdrop
that the Evaluation of Genomic Applications in Practice
and Prevention (EGAPP) working group was formed to
guide best practices in experimental design and the in-
terpretation of evidence for utility in clinical practice
[23]. Fundamental to EGAPP criteria is the concept that
clinical utility requires not only clinical validity (linking
test results to clinical presentation, treatment and out-
come), but just as importantly, analytical validity (the
capacity of the test classifier to be sensitive, specific andreproducible in practice). However, EGAPP found that
relatively few studies of breast cancer molecular classifiers
have directly reported on analytical reproducibility [38].
Analytical reproducibility is a requirement for the im-
plementation of all diagnostic tests, but it is especially
critical for decentralized tests given the challenges of
maintaining reproducibility across pathologists, technical
operators, and instrumentation. However, decentralized
tests also have many advantages over Laboratory Devel-
oped Tests that are performed at single central labora-
tories. By avoiding the need for shipping tissues,
turnaround times and costs are reduced. The capacity
for the laboratory physician to interact directly with the
treating physician greatly aids medical care, for example in
facilitating appropriate prioritization of critical specimens,
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recognizing inadequate specimens and what can be done
to get a result helpful to the patient as soon as possible.
Although first generation breast cancer prognostic tests
were performed in central labs [32], second generation
tests are being developed and validated to realize the ad-
vantages of decentralized testing [39].
The Prosigna assay was tested across a range of RNA
mass inputs that is consistent with what will be expected
in a clinical lab setting. The assay is robust across that
range, similar to what has been reported with other mul-
tigene breast cancer tests [32,39]. Additionally, the assay
gave consistent results outside the specified assay RNA
input limits; only 2 samples failed to produce passing re-
sults at half the lowest specified mass further illustrating
the robustness of the assay.
The observation of biased subtype calls and ROR scores
with the inclusion of non-tumor tissue is consistent with a
prior study [40], however the bias reported herein is less
severe. Similar to what is expected to be experienced in
clinical practice, the interferent being measured here is re-
ported as percent adjacent non-tumor tissue included, ra-
ther than percent non-tumor RNA from a separate paired
normal tissue sample reported in the earlier study. Normal
breast tissue yields less total RNA compared to tumor tis-
sue [41] and adjacent non-tumor tissue at the margins of
the tumor have certain cancer pathways activated where
matched healthy breast does not [42,43]. Nonetheless, this
study illustrates the importance of performing the
macrodissection according to the defined procedure to
maximize the accuracy of the test.
The precision and reproducibility of the Prosigna
assay, estimated from repeat measurements of pooled
tumor RNA sample(s) and de-identified patient tissue
samples across multiple testing sites is similar (relative
to the overall test range) to what was previously re-
ported for centralized lab tests [32,38]. These results
demonstrate that the Prosigna assay is analytically repro-
ducible even when performed at multiple test sites and
including all process variables. It will be important for
local labs to verify the reproducibility reported herein
when implementing this decentralized assay to ensure the
quality of the test’s results, including ongoing process
monitoring [38].
Our experience of implementing the nCounter plat-
form in our CLIA-certified hospital laboratory environ-
ments proved to be straightforward, confirming the
simplicity of the assay and its suitability as an in vitro
diagnostic test. Training of the assay workflow (includ-
ing tissue macrodissection, RNA isolation and setup of
Prosigna assay) takes less than one week. The pre-
specified SOPs are easy to follow and the procedure of
RNA extraction and Prosigna assay are straightforward.
All operators, most of whom were naïve users to theProsigna assay, were able to pass the training procedures
on the first attempt, before executing the pre-specified
study protocols. Although overnight incubations are re-
quired during RNA extraction and RNA – probe
hybridization, the incubation temperature is constant, and
hands-on time requirements for the whole experiment are
very limited. Furthermore, the analyses for subtype call
and ROR score are simplified and controlled by integrat-
ing the algorithm into the software for raw data process-
ing, reducing the potential for human error in data
cleaning and analysis.
Conclusion
The FDA cleared and CE marked Prosigna assay based on
the PAM50 gene expression signature has recently been
shown to predict the risk of distant recurrence in women
with hormone receptor positive early stage breast cancer
treated with five years of endocrine therapy [19,20]. This
demonstration of analytical reproducibility generates a
strong body of evidence supporting the decentralized use
of this test as a tool for breast cancer risk stratification.
Additional ongoing studies of the clinical validity of the
PAM50 gene expression signature for chemosensitivity
prediction [34-36] could, if confirmed, be considered clin-
ically actionable given the demonstrated analytical validity
of this test.Additional files
Additional file 1: Table S1. Site to site ROR sample means. Mean ROR
scores were calculated for each pooled RNA sample, and likelihood ratio
test for significance was performed to test for differences between sites.
There were no significant differences in the results observed across sites
for the five pooled RNA samples tested. All p-values were well above 0.05
for the likelihood ratio test of significance of site with 2 degrees of
freedom for each pooled RNA sample. The differences in means between
sites were all less than 0.5 ROR units on a 0-100 scale.
Additional file 2: Table S2. Within site gene expression comparisons
from the tissue reproducibility study. Pairwise correlations, slopes, and
intercepts of normalized 50 genes for replicate RNA Hybridizations from
the tissue reproducibility study. The average intercept, slope, and
Pearson’s correlation of the pair-wise comparisons are reported with the
95% confidence interval.
Additional file 3: Figure S1. Hierarchical clustering of all samples from
the tissue reproducibility study. Clustering analysis (using a Pearson’s
distance metric and average linkage) was performed on the median
centered normalized, Log2 transformed and scaled sample data to
further characterize the gene expression in the tissue samples. The tissue
sample and RNA sample replicates were always only clustered together
and the node heights are almost imperceptibly low (indicating highly
correlated gene expression).
Additional file 4: Figure S2. Average ROR Score for the 13 unique
tumor RNA samples within the RNA Input Study. Data are colored by the
intrinsic subtype result at 250 ng of RNA.
Additional file 5: Figure S3. ROR Score for the 23 unique
macrodissected tumor samples. Data are colored by the intrinsic subtype
result for each tissue. For tissues with multiple isolations the subtype result
illustrated was from the macrodissection with the most number of slides
processed.
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